NCT06436911View on ClinicalTrials.gov

To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions
COVID-19
Interventions
DRUG

COVIGENIX VAX- 002

ENTVAX-001-01

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

University of Alberta, Edmonton

L7M4Y1

RECRUITING

Centricity Research, Burlington

M4G3E8

RECRUITING

Centricity Research, Toronto

M9W4L6

RECRUITING

Centricity Research, Toronto

G1V4T3

RECRUITING

Diex Recherche Quebec, Québec

J1L0H8

RECRUITING

Diex Recherche, Sherbrooke

Sponsors
All Listed Sponsors
collaborator

Calian CRO

UNKNOWN

collaborator

Q2 Solutions

INDUSTRY

collaborator

PCI Pharma Services

UNKNOWN

lead

Entos Pharmaceuticals Inc.

INDUSTRY